Create account

Coverage dated August 7, 2023 to August 9, 2023

Novo Nordisk to acquire obesity drug maker Inversago Pharma for up to $1 billion

Headline from NBC10 Philadelphia, on the newest of 2 developments

Inversago’s drugs use a different approach than most treatments in the obesity and diabetes space.

NBC10 Philadelphia's own description from its feed. We collect headlines and these descriptions, not full articles; read the original reporting below.

Developments in this update

2 dated developments, oldest first, newest marked. Each is named by one outlet's own headline; open its reports to see every outlet that covered it.

  1. Weight-Loss Drug Wegovy Lowers Major Heart Disease Risk By 20%, Trial Says—Novo Nordisk Shares Surge

    Headline from Forbes ·

  2. Newest

    Novo Nordisk to acquire obesity drug maker Inversago Pharma for up to $1 billion

    Headline from NBC10 Philadelphia ·

Read the reports

Reports & sources

13 articles, oldest first.

  1. Forbes

    Weight-Loss Drug Wegovy Lowers Major Heart Disease Risk By 20%, Trial Says—Novo Nordisk Shares Surge (opens Forbes)

    Published

    Forbes's feed description

    Novo Nordisk’s shares rose by more than 16% on Tuesday, as the results of the trial exceeded investor expectations.

  2. Forbes

    Novo Nordisk’s Huge Financial Bet On Obesity Drug Wegovy Wins Big (opens Forbes)

    Published

    Forbes's feed description

    The SELECT trial is a game changer. Yes, Novo Nordisk achieved winning results. But obesity patients with heart disease now have a major new drug to extend their lives – and that’s an even bigger win.

  3. NBC 5 Dallas-Fort Worth

    Novo Nordisk shares pop after key trial data shows Wegovy cuts risk of heart attack or stroke by 20% (opens NBC 5 Dallas-Fort Worth)

    Published

    NBC 5 Dallas-Fort Worth's feed description

    The results of the trial were seen as a major boost for the firm’s hopes of moving beyond Wegovy’s image as a “vanity drug.”

  4. NBC10 Philadelphia

    Novo Nordisk to acquire obesity drug maker Inversago Pharma for up to $1 billion (opens NBC10 Philadelphia)

    Published

    NBC10 Philadelphia's feed description

    Inversago’s drugs use a different approach than most treatments in the obesity and diabetes space.

  5. NBC 6 South Florida

    Wegovy-maker Novo Nordisk sales soar 30% on strong demand for its weight-loss drug (opens NBC 6 South Florida)

    Published

    NBC 6 South Florida's feed description

    The Danish company’s diabetes and obesity division performed particularly well, bolstered by interest in its blockbuster injections Wegovy and Ozempic.

  6. Wall Street Journal

    Novo Nordisk Raises Guidance Amid Surging Demand for Diabetes, Obesity Drugs (opens Wall Street Journal)

    Published

    Wall Street Journal's feed description

    Novo Nordisk now expects 2023 sales growth of 27%-33% and operating profit growth of 31%-37%, as demand for its Ozempic diabetes drug and Wegovy obesity treatment continued to rise.

  7. UPI

    Novo Nordisk plans to acquire Canadian obesity drug maker Inversago (opens UPI)

    Published

    UPI's feed description

    Drug manufacturer Novo Nordisk announced Thursday that it will acquire Inversago Pharma, a Montreal-based company that develops potential treatments for obesity, if certain research conditions are met, for $1.075 billion

  8. Bloomberg

    Novo Raises Outlook on Demand for Obesity Blockbusters (opens Bloomberg)

    Published

    Bloomberg's feed description

    Novo Nordisk A/S said the supply of its blockbuster obesity medicine Wegovy will continue to be restricted in the US as the drugmaker struggles to increase capacity.

  9. NBC10 Philadelphia

    Wegovy-maker Novo Nordisk raises outlook as sales of its weight-loss drug soar (opens NBC10 Philadelphia)

    Published

    NBC10 Philadelphia's feed description

    The Danish company’s diabetes and obesity division performed particularly well, bolstered by interest in its blockbuster injection Wegovy.

Identical headlines usually mean shared wire copy. They are counted as separate articles but are not independent confirmation.

Novo Nordisk to acquire obesity drug maker Inversago Pharma for up to $1 billion | Since Then